AI-generated from publicly available materials.Biograph has successfully completed its inaugural U.S. study utilizing Caristo Diagnostics’ AI-driven technology to detect coronary inflammation in asymptomatic individuals, revealing significant cardiovascular risks often overlooked by traditional assessments.
The study, which involved Biograph's advanced diagnostic tools such as high-resolution coronary computed tomography angiography (CCTA), found that over 42% of asymptomatic, low-risk adults exhibited signs of coronary inflammation. This condition frequently occurred without any visible plaque or blockage, indicating a gap in conventional cardiovascular risk assessments. Notably, nearly half of the participants with no detectable plaque still showed elevated inflammation levels, suggesting that standard metrics like cholesterol and blood sugar tests are insufficient for identifying hidden risks.
Dr. Michael Doney, Biograph's Executive Medical Director, emphasized the implications of these findings, pointing out that traditional biomarkers failed to detect inflamed arteries in individuals who otherwise appeared healthy. This raises concerns about the current methods of cardiovascular risk evaluation and underscores the potential for early intervention in managing heart disease.
This study aligns with Biograph's mission to enhance proactive healthcare through comprehensive diagnostics, highlighting the importance of understanding coronary inflammation as an early indicator of cardiovascular issues. The findings advocate for a shift in how cardiovascular health is monitored, suggesting that more nuanced approaches could lead to better long-term health outcomes.